Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Crescent Biopharma (CBIO) Depreciation and Depletion (2016 - 2025)

Crescent Biopharma (CBIO) has disclosed Depreciation and Depletion for 11 consecutive years, with $54000.0 as the latest value for Q4 2025.

  • Quarterly Depreciation and Depletion changed N/A to $54000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $56000.0 through Dec 2025, changed N/A year-over-year, with the annual reading at $84000.0 for FY2025, 138.81% up from the prior year.
  • Depreciation and Depletion for Q4 2025 was $54000.0 at Crescent Biopharma, up from -$12620.0 in the prior quarter.
  • The five-year high for Depreciation and Depletion was $68088.0 in Q1 2021, with the low at -$12620.0 in Q2 2025.
  • Average Depreciation and Depletion over 5 years is $45403.3, with a median of $47347.0 recorded in 2022.
  • The sharpest move saw Depreciation and Depletion grew 1.29% in 2021, then tumbled 66.65% in 2024.
  • Over 5 years, Depreciation and Depletion stood at $61643.0 in 2021, then dropped by 25.83% to $45718.0 in 2022, then tumbled by 49.04% to $23297.0 in 2023, then plummeted by 37.25% to $14620.0 in 2024, then skyrocketed by 269.36% to $54000.0 in 2025.
  • According to Business Quant data, Depreciation and Depletion over the past three periods came in at $54000.0, -$12620.0, and $14620.0 for Q4 2025, Q2 2025, and Q1 2024 respectively.